An agreement on the United States–Mexico–Canada Agreement (USMCA), a trade deal that updates the North American Free Trade Agreement, has been reached, and proponents of biosimilars and generics have cause to celebrate after the removal of provisions that some said would hinder competition.
An agreement on the United States—Mexico–Canada Agreement (USMCA), a trade deal that updates the North American Free Trade Agreement, has been reached, and proponents of biosimilars and generics have cause to celebrate after the removal of provisions that some said would hinder competition.
The full text of the newly agreed version of the deal is yet to be publicly released. However, the chairman of the House Committee on Ways and Means, Richard Neal, D-Massachusetts, said in a statement outlining features of the final agreement that House Democrats were successful in their attempts to remove provisions of the deal that would have required all parties to provide at least 10 years of exclusivity for biologic drugs, to remove provisions that would have allowed patent evergreening on drugs, and to cut provisions that would allow 3 extra years of exclusivity for clinical information submitted in connection with new uses of existing products.
The revised agreement also includes clarification on circumstances in which generic and biosimilar developers can use patented inventions in order to gain marketing approval on the first day after patent expiry.
Biosimilars and generics trade group the Association for Accessible Medicines called the revised deal a victory for patients, saying that the new agreement creates greater opportunities for patients in all 3 nations to access less expensive prescription drugs.
The Canadian Generic Pharmaceutical Association also praised the deal; president Jim Keon said that the removal of the 10-year exclusivity provision is particularly important for Canadian patients, noting that the provision could have delayed the availability of biosimilar medicines in Canada, where biosimilars are increasingly seen as a crucial part of national attempts to reduce prescription drug costs.
In the United States, AARP’s executive vice president and chief advocacy and engagement officer, Nancy LeaMond, said in a statement that “there is no reason why the [United States] should continue to pay the highest drug prices in the world. Americans, along with our Canadian and Mexican neighbors, scored a noteworthy victory today against ‘big pharma’ that pushed hard to keep these provisions in the USMCA.”
Perhaps unsurprisingly, the Pharmaceutical Research and Manufacturers of America, or PhRMA, which represents innovator drug makers, took a dim view of the revisions; president and chief executive officer Stephen J. Ubl said that removal of biologics exclusivity provisions would do “nothing” to help patients, and that the revised deal will help foreign governments “who want to steal American intellectual property and free ride on America’s global leadership."
Similarly, the Biotechnology Innovation Organization, which represents biotech companies, said that the United States had given up an important tool to “end foreign free-riding on American medical innovation.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.